CYP3A4 and neoplasm: Hence, we evaluated the inhibitory effects of diflavonoids toward three clinical drugs that mainly undergo CYP3A4-mediated metabolism including anticoagulant agent ticagrelor, anti-tumor drug tamoxifen, and gefitinib.